CMTFX
Price
$132.05
Change
-$2.56 (-1.90%)
Updated
Jul 24 closing price
Net Assets
5.18B
PRGTX
Price
$33.46
Change
-$0.86 (-2.51%)
Updated
Jul 24 closing price
Net Assets
7.84B
Interact to see
Advertisement

CMTFX vs PRGTX

CMTFX vs PRGTX Comparison Chart in %
View a ticker or compare two or three
VS
CMTFX vs. PRGTX commentary
Jul 26, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMTFX is a Hold and PRGTX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
PRGTX has more cash in the bank: 7.84B vs. CMTFX (5.18B). CMTFX (0.00) and PRGTX (0.00) have matching dividends . CMTFX was incepted earlier than PRGTX: CMTFX (26 years) vs PRGTX (26 years). PRGTX (0.93) and CMTFX (0.91) have similar cost to investors . PRGTX is a more actively managed with annual turnover of: 34.60 vs. CMTFX (6.00). CMTFX has a lower initial minimum investment than PRGTX: CMTFX (2000) vs PRGTX (2500). PRGTX annual gain was more profitable for investors over the last year : 40.82 vs. CMTFX (30.30). CMTFX return over 5 years is better than : 90.37 vs. PRGTX (4.33).
CMTFXPRGTXCMTFX / PRGTX
Total Expense Ratio0.910.9398%
Annual Report Gross Expense Ratio0.910.9398%
Fund Existence26 years26 years-
Gain YTD21.24826.02682%
Front LoadN/AN/A-
Min. Initial Investment2000250080%
Min. Initial Investment IRAN/AN/A-
Net Assets5.18B7.84B66%
Annual Yield % from dividends0.000.00-
Returns for 1 year30.3040.8274%
Returns for 3 years104.92129.8181%
Returns for 5 years90.374.332,085%
Returns for 10 years529.90134.81393%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHPAX22.810.16
+0.71%
Saratoga Health & Biotechnology A
FDTZX27.050.01
+0.04%
Fidelity Advisor Capital Development M
KGDIX39.05-0.16
-0.41%
DWS Global Small Cap Inst
SCMGX22.15-0.13
-0.58%
Sands Capital Global Growth Inst
TEMPX11.38-0.25
-2.15%
Nuveen Emerging Markets Eq Prem